ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).

R. Knight,1 S. Patel,1 J. Loucks-DeVos,2 S. Kuten,1 A. Gaber.1

1Houston Methodist Hospital, Houston, TX
2Kansas University Medical Center, Kansas City, KS.

Meeting: 2016 American Transplant Congress

Abstract number: A231

Keywords: Alloantibodies, HLA antibodies, Immunoglobulins (Ig), Kidney transplantation

Session Information

Date: Saturday, June 11, 2016

Session Name: Poster Session A: Long Term Outcomes in Kidney Transplantation

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Related Abstracts
  • De Novo Donor Specific Antibody (DSA) After Treatment of BK Infection With Intravenous Immunoglobulin (IVIG)
  • Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab

Intravenous immune globulin (IVIG) may be beneficial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term follow-up of stable RTR with DSA treated with IVIG. Methods: We prospectively monitored all RTR from 7/2007-7/2012 for DSA at 1, 3, 6, 9 and 12 months, then bi-annually. RTR positive for DSA on ≥2 occasions underwent biopsy. In 2012, recipients with DSA and no AR received IVIG 1 g/kg monthly x 6 months after attaining insurance approval (IVIG, n=12). Outcomes were compared to RTR denied insurance approval or who were otherwise unable to receive IVIG (No IVIG, n=14). Results: IVIG patients were more likely to be white, female, and living donor recipients (Table 1). Mean follow-up was 46±14 months post-DSA onset. One patient stopped IVIG after the 5th dose due to a flu-like reaction, otherwise IVIG was well-tolerated. DSA-related outcomes are shown below.

Table 1. Baseline Characteristics IVIG (n=12) No IVIG (n=14)
Age, years 50±13 48±13

Race, n(%)

  Black

  White

 

4(33)

4(33)

 

6(43)

2(14)

Female gender, n(%) 8(67) 6(43)
Living donor recipient, n(%) 4(33) 2(14)
Peak PRA, % 47±41 35±35
HLA mismatches/6 3.9±2 5±1
Table 2. DSA-Related Outcomes IVIG (n=12) No IVIG (n=14)
BPAR following DSA, n(%) 8 (67) 5 (36)
Time DSA onset to BPAR, days 500±453 596±349
Graft loss, n(%) 2(17) 3(21)
Causes of graft loss

Chronic TG (1)

Death (1)

IFTA following BPAR and chronic ureteral obstruction (1)

Chronic rejection/diabetic nephropathy (1)

Death (1)

Most recent Cr, mg/dL 1.4±0.6 1.3±0.6
DSA negative at last follow-up, n(%) 4(33) 7(50)
# of DSA specificities at last follow-up 1.6±0.7 (n=8) 1±0 (n=7)

Conclusion: In a pilot study of IVIG for treatment of DSA, we did not observe any discernible impact on DSA clearance or MFI reduction. Graft function was similar to those who did not receive IVIG. Larger studies and/or alternate dosing regimens may be required to determine the role of IVIG for treatment of DSA.

CITATION INFORMATION: Knight R, Patel S, Loucks-DeVos J, Kuten S, Gaber A. Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA). Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Knight R, Patel S, Loucks-DeVos J, Kuten S, Gaber A. Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA). [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-follow-up-of-renal-transplant-recipients-rtr-treated-with-ivig-for-de-novo-donor-specific-antibodies-dsa/. Accessed April 20, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.